Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxen vs Standard of Care for Post-Mohs Pain
NCT06948513Phase 3Completed
- Sponsor
- Zitelli & Brodland Skin Cancer Center
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naproxen in postoperative pain (2 arms), sponsored by Zitelli & Brodland Skin Cancer Center. Primary endpoint: Patient reported pain score at 10 hours. Started Dec 2022; status: completed.
02
Drugs
naproxen
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06948513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948513.